Recently, rituximab, an antibody specifically targeting B‐cell depletion initially for lymphoma treatment, has gradually presented potential advantages as an off‐label attempt in treating CIDP or other autoimmune neuropathies caused by nodal–paranodal neurofascin (NF), contactin 1 (CNTN1), and contactin‐associated protein 1 (Caspr1) antibodies.13, 14, 15, 16. Here, NFASC is linked to chronic inflammatory demyelinating polyradiculoneuropathy.